England’s Cost Effectiveness Rejection Is Another Setback For Eisai And Biogen’s Leqembi

 
• By Andrew McConaghie
  
Alzheimer's jigsaw
• Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip